

MARQUARDT DAVID F  
Form 4  
May 17, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MARQUARDT DAVID F

(Last) (First) (Middle)

C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY

(Street)

REDMOND, WA 98052-6399

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
MICROSOFT CORP [MSFT]

3. Date of Earliest Transaction (Month/Day/Year)  
05/14/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	05/14/2013		G	V 6,155 D \$ 0	671,431	D	
Common Stock					1,325	I	By daughter
Common Stock					1,325	I	By son
Common Stock					1,325	I	By son

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MARQUARDT DAVID F C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND, WA 98052-6399	X			

## Signatures

Keith R. Dolliver, Attorney-in-Fact for David F. Marquardt  
Date: 05/17/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.  
omethasone dipropionate); corticosteroid Current(Glaxo/Beconase) CTD  
----- Formulation: Pulmonary/nasal Oral tablets (dual release) (Beconase(R)/Glaxo) Therapeutic Indication: Asthma Treatment of Intestinal Graft vs. Host Disease; other gastro disorders Development Status: Marketed Phase 3 multicenter trials; Orphan drug/FDA "fast-track designation" Market: \$500 M/year 2500-5100 patients/year (15-30% of allogeneic bone marrow transplant patients) CORPORATE TECHNOLOGY DEVELOPMENT, INC KEY PRODUCTS Oraprine(R) (azathioprine); immunosuppressant Current(Faro/Imuran(R)

CTD ----- --- Formulation: I.V./Tablet Oral (liquid) Therapeutic Indication: Treatment of: Same -  
transplant rejection Oral GVHD - rheumatoid arthritis Development Status: Marketed Phase 1 bioequivalency trial  
Phase 1/2 trial for chronic oral autoimmune diseases completed; Orphan drug ENDOREX/CTD PRODUCT  
PIPELINE [Graphical image of a chart depicting product candidates of Endorex and CTD with arrows indicating the  
different stages of development for the following product candidates: orBec(TM) - I GVHD [arrow indicates initial  
Phase 3 development stage] - Other GI Disorders [arrow indicates development stage between Phase 1 and Phase 2]  
Oraprine(R) - Oral autoimmune disorders [arrow indicates development stage between Phase 1 and Phase 2] -  
Rheumatoid arthritis/transplant [arrow indicates Initial Phase 1 development stage] Oral Delivery - Insulin [arrow  
indicates development stage between research and preclinical] - Human Growth Hormone [arrow indicates  
development stage between research and preclinical] - Tetanus Vax [arrow indicates development stage between  
research and preclinical] - Influenza Vax [arrow indicates development stage between research and preclinical] - Other  
Drugs [arrow indicates research development stage] ACQUISITION OF CTD - Endorex to acquire CTD for 10  
million shares: - 9.4 million common shares - .6 million warrants/options - Endorex to integrate CTD  
management/board: - 3 members to join Endorex board - Chairman Colin Bier, Ph.D., to assume position of Endorex  
Chairman/CEO ENDOREX CAPITAL STRUCTURE POST ACQUISITION Shares - Millions Outstanding  
Fully-Diluted ----- Endorex 12.7 19.8 Endorex + CTD 22.1 29.8 CTD ownership of Endorex 44%  
33% SYNERGY OF COMPANIES Oral/Mucosal Delivery ENDOREX MACROMOLECULES PRECLINICAL  
hGH Insulin Vaccines Other Management Public \$9.5M cash CTD SMALL MOLECULES CLINICAL orBec(TM)  
phase 3 Oraprine(R) phase 1-2 Management Private \$5.0M cash ENDOREX ORAL/MUCOSAL DELIVERY  
Endorex CTD - Clinical/preclinical pipeline - Expanded patent portfolio - Enhanced management - Strengthened  
balance sheet ENDOREX HIGHLIGHTS - Oral drug delivery technology addresses significant market: - Biotech  
injectable products - \$18.5 billion - Other drugs with delivery issues - Business strategy for extending patent and  
commercial life of existing drugs via new delivery systems - Strong intellectual property portfolio: 50+ issued patents  
- New company acquisition strengthens drug pipeline, balance sheet and management team THANK YOU  
WELCOME TO A BRAVE NEW WORLD OF NO MORE NEEDLES [Photographic image depicting a hand holding  
a syringe.]